Adverse reactions to sulphasalazine and 5-amino salicylic acid in the same patient.

abstract：AIM:To compare the antisecretory effects of rabeprazole and esomeprazole in an open, randomized, two-way crossover, clinical pharmacology study. METHODS:Twenty-four healthy subjects (14 men, 10 women; mean age 26.8 years) received rabeprazole 20 mg or esomeprazole 20 mg daily on days 1-5, with a 14-day 'wash-out'. Int...

journal_title：Alimentary pharmacology & therapeutics

authors： Warrington S,Baisley K,Boyce M,Tejura B,Morocutti A,Miller N

更新日期：2002-07-01 00:00:00

abstract：BACKGROUND:Infection is the most common cause of mortality in end-stage liver disease (ESLD). The impact of obesity on infection risk in ESLD is not established. AIM:To characterise the impact of obesity on infection risk in ESLD. METHODS:We evaluated the association between infection and obesity in patients with ESL...

journal_title：Alimentary pharmacology & therapeutics

authors： Sundaram V,Kaung A,Rajaram A,Lu SC,Tran TT,Nissen NN,Klein AS,Jalan R,Charlton MR,Jeon CY

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:Clostridium difficile (C. difficile) infection in hospitals in developed countries continues to be a major public health hazard despite increased control measures including review of antibiotic policies and hygiene measures. Patients with colitis are thought to be particularly vulnerable to C. difficile asso...

journal_title：Alimentary pharmacology & therapeutics

authors： Jen MH,Saxena S,Bottle A,Aylin P,Pollok RC

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM:To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS:A r...

journal_title：Alimentary pharmacology & therapeutics

authors： Ma C,Fedorak RN,Kaplan GG,Dieleman LA,Devlin SM,Stern N,Kroeker KI,Seow CH,Leung Y,Novak KL,Halloran BP,Huang VW,Wong K,Blustein PK,Ghosh S,Panaccione R

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Approximately 20% of primary sclerosing cholangitis (PSC) patients with concomitant inflammatory bowel disease (IBD) have Crohn's disease (CD). AIM:To compare PSC/CD with other PSC patients. METHODS:Retrospective study of 240 PSC patients diagnosed between 1975 and 2012 (median follow-up 12 years). Activit...

journal_title：Alimentary pharmacology & therapeutics

authors： Fevery J,Van Steenbergen W,Van Pelt J,Laleman W,Hoffman I,Geboes K,Vermeire S,Nevens F

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Diagnosis of inflammatory bowel disease (IBD) is based on clinical presentation, colonoscopy and histology. Differentiation of Crohn's disease (CD) and ulcerative colitis (UC) can be difficult in some patients. Endoscopic ultrasound (EUS) provides high resolution images of the gastrointestinal wall (GI) and ...

journal_title：Alimentary pharmacology & therapeutics

authors： Ellrichmann M,Wietzke-Braun P,Dhar S,Nikolaus S,Arlt A,Bethge J,Kuehbacher T,Wintermeyer L,Balschun K,Klapper W,Schreiber S,Fritscher-Ravens A

更新日期：2014-04-01 00:00:00

abstract：:The pathogenesis of cholesterol gallstones is now recognized as a multifactorial process, including saturation of bile with cholesterol, destabilization of bile leading to cholesterol crystals and hypomotility permitting crystal growth, and agglomeration and retention of microstones which then grow to macroscopic gall...

journal_title：Alimentary pharmacology & therapeutics

authors： Pauletzki J,Paumgartner G

更新日期：2000-05-01 00:00:00

abstract：:The study investigated the oral absorption of two antifungal agents, fluconazole and itraconazole, under conditions of low intragastric acidity. Twelve healthy male volunteers received each of 4 dosing regimens: 200 mg itraconazole alone, 200 mg itraconazole and famotidine, 100 mg fluconazole alone, and 100 mg flucona...

journal_title：Alimentary pharmacology & therapeutics

authors： Lim SG,Sawyerr AM,Hudson M,Sercombe J,Pounder RE

更新日期：1993-06-01 00:00:00

abstract：BACKGROUND:Application of electrical stimulation to the gut, primarily the stomach, has rapidly advanced in the last two decades, from mostly animal studies to the clinical arena. Most studies focused on the use of electrical stimulation for gastroparesis, the only approved indication for such intervention. AIM:To rev...

journal_title：Alimentary pharmacology & therapeutics

authors： Soffer E,Abell T,Lin Z,Lorincz A,McCallum R,Parkman H,Policker S,Ordog T

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:Currently, the relationship between depression and non-alcoholic fatty liver disease (NAFLD) is not clearly defined. AIM:To determine whether depression is associated with NAFLD and NAFLD-related advanced fibrosis in a large population sample. METHODS:We performed a cross-sectional analysis using the 2007-...

journal_title：Alimentary pharmacology & therapeutics

authors： Kim D,Yoo ER,Li AA,Tighe SP,Cholankeril G,Harrison SA,Ahmed A

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Hepatocellular carcinoma (HCC) risk after resolving chronic hepatitis B virus (HBV) infection is unclear. AIM:To compare HCC risk between Alaska Native (AN) patients with and without hepatitis B surface antigen (HBsAg) seroclearance. METHODS:We selected persons with (case-patients) and without (control-pat...

journal_title：Alimentary pharmacology & therapeutics

authors： Gounder PP,Bulkow LR,Snowball M,Negus S,Spradling PR,Simons BC,McMahon BJ

更新日期：2016-06-01 00:00:00

abstract：BACKGROUND:Small intestinal bacterial overgrowth and sugar malabsorption (lactose, fructose, sorbitol) may play a role in irritable bowel syndrome. The lactulose breath test is a reliable and non-invasive test for the diagnosis of small intestinal bacterial overgrowth. The lactose, fructose and sorbitol hydrogen breath...

journal_title：Alimentary pharmacology & therapeutics

authors： Nucera G,Gabrielli M,Lupascu A,Lauritano EC,Santoliquido A,Cremonini F,Cammarota G,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

更新日期：2005-06-01 00:00:00

abstract：:The aetiology of Crohn's disease is unknown and therefore no curative treatments are available for the disease. The natural history of Crohn's disease is characterized by recurrent flare-ups of symptoms. Several drug treatments are effective in inducing clinical remission. However, no drug treatments are available in ...

journal_title：Alimentary pharmacology & therapeutics

authors： Biancone L,Tosti C,Fina D,Fantini M,De Nigris F,Geremia A,Pallone F

更新日期：2003-06-01 00:00:00

abstract：BACKGROUND:Hepatic encephalopathy has a negative effect on patient health-related quality of life (HRQOL). Zinc supplementation has been effective with regard to altered nitrogen metabolism. AIM:To investigate the effectiveness of oral zinc supplementation on hepatic encephalopathy and HRQOL. METHODS:Seventy-nine cir...

journal_title：Alimentary pharmacology & therapeutics

authors： Takuma Y,Nouso K,Makino Y,Hayashi M,Takahashi H

更新日期：2010-11-01 00:00:00

abstract：BACKGROUND:Predicting factors for the outcome of conventional Helicobacter pylori triple therapy have been identified. Of these, the presence of the CagA gene is a strong predictor of successful treatment. Our preliminary data show that this factor becomes irrelevant when sequential therapy is used. AIM:To identify pr...

journal_title：Alimentary pharmacology & therapeutics

authors： De Francesco V,Zullo A,Margiotta M,Marangi S,Burattini O,Berloco P,Russo F,Barone M,Di Leo A,Minenna MF,Stoppino V,Morini S,Panella C,Francavilla A,Ierardi E

更新日期：2004-02-15 00:00:00

abstract：BACKGROUND:Different authors have postulated both toxic and protective effects for nitric oxide (NO) in the pathophysiology of active inflammation. AIM:To examine the role of NO, especially that produced by the inducible form of nitric oxide synthase (iNOS), by investigating the effects of NOS inhibitors and NO donors...

journal_title：Alimentary pharmacology & therapeutics

authors： Yoshida Y,Iwai A,Itoh K,Tanaka M,Kato S,Hokari R,Miyahara T,Koyama H,Miura S,Kobayashi M

更新日期：2000-04-01 00:00:00

abstract：BACKGROUND:The seroclearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) is considered to be associated with favourable clinical outcomes. AIMS:This meta-analysis was performed to establish the proportion of HBsAg loss rates among CHB patients who received combination treatment ba...

journal_title：Alimentary pharmacology & therapeutics

authors： Qiu K,Liu B,Li SY,Li H,Chen ZW,Luo AR,Peng ML,Ren H,Hu P

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:In patients with pruritus of cholestasis, response to conventional drug treatment may be unsatisfactory. Activation of 5-hydroxytryptamine receptors on dermal sensory nerve-endings plays a role in the perception of pruritus. The 5-hydroxytryptamine(3) receptor antagonist, ondansetron, has been used in the tr...

journal_title：Alimentary pharmacology & therapeutics

authors： O'Donohue JW,Pereira SP,Ashdown AC,Haigh CG,Wilkinson JR,Williams R

更新日期：2005-04-15 00:00:00

abstract：BACKGROUND:Comparative long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high-risk patients with chronic hepatitis B (CHB)-related compensated cirrhosis is controversial. AIMS:To compare the long-term efficacy of ...

journal_title：Alimentary pharmacology & therapeutics

authors： Hu TH,Yueh-Hsia Chiu S,Tseng PL,Chen CH,Lu SN,Wang JH,Hung CH,Kee KM,Lin MT,Chang KC,Lin MC,Chien RN

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Peristomal wound infections are common complications of percutaneous endoscopic gastrostomy (PEG), especially in hospitals where methicillin-resistant Staphylococcus aureus (MRSA) is endemic. Evidence suggests that antibiotic prophylaxis at PEG insertion may reduce infection rates. AIM:To examine rates of p...

journal_title：Alimentary pharmacology & therapeutics

authors： Thomas S,Cantrill S,Waghorn DJ,McIntyre A

更新日期：2007-03-01 00:00:00

abstract：BACKGROUND:Nocturnal gastro-oesophageal reflux diseases (GERD) can lead to oesophageal mucosal injury and extra-oesophageal complications. AIM:To compare distribution of oesophageal acid exposure during sleep time among patients with non-erosive reflux disease and abnormal pH test (NERD-positive), erosive oesophagitis...

journal_title：Alimentary pharmacology & therapeutics

authors： Dickman R,Parthasarathy S,Malagon IB,Jones P,Han B,Powers J,Fass R

更新日期：2007-07-01 00:00:00

abstract：BACKGROUND:Steroid-refractory ulcerative colitis (UC) remains a challenging condition warranting surgery upon failure of pharmacological treatment. Calcineurin inhibitors or infliximab are alternatives in this situation. Data on the efficacy and safety of tacrolimus in this setting are limited. AIM:To study the short-...

journal_title：Alimentary pharmacology & therapeutics

authors： Schmidt KJ,Herrlinger KR,Emmrich J,Barthel D,Koc H,Lehnert H,Stange EF,Fellermann K,Büning J

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Population data supporting an association between the autoimmune cholestatic liver diseases, primary biliary cirrhosis and primary sclerosing cholangitis and coeliac disease, is limited and at times contradictory. AIM:To explore the relationship between coeliac disease and both primary biliary cirrhosis and...

journal_title：Alimentary pharmacology & therapeutics

authors： Lawson A,West J,Aithal GP,Logan RF

更新日期：2005-02-15 00:00:00

abstract：BACKGROUND:The efficacy of each probiotic should be evaluated separately. Previously, we have shown that Lactobacillus GG (LGG) is effective in treating acute gastroenteritis (AGE) in children. AIM:To update our 2007 meta-analysis on the effectiveness of LGG in treating AGE in children. METHODS:The Cochrane Library, ...

journal_title：Alimentary pharmacology & therapeutics

authors： Szajewska H,Skórka A,Ruszczyński M,Gieruszczak-Białek D

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Previous epidemiological studies suggest that patients diagnosed with nonalcoholic fatty liver disease (NAFLD) who drink light to moderate amounts of alcohol (up to ~30 g per day) have less severe histological lesions compared with nondrinkers. However, while the cross-sectional nature of current evidence pr...

journal_title：Alimentary pharmacology & therapeutics

authors： Sookoian S,Flichman D,Castaño GO,Pirola CJ

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Colitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy. AIMS:To investigate associations between clinical, endoscopic, and histological features with outcomes METHODS: We identified 149 patients from seven institutio...

journal_title：Alimentary pharmacology & therapeutics

authors： Pai RK,Pai RK,Brown I,Choi WT,Schaeffer DF,Farnell D,Kumarasinghe MP,Gunawardena D,Kim BH,Friedman M,Ghayouri M,Lauwers GY

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:Patients with chronic liver disease and components of metabolic syndrome may be at higher risk for fibrosis. AIM:To assess the impact of clinicodemographic factors on hepatic fibrosis in CLD. METHODS:Of 1028 chronic liver disease patients, 964 were included in the analysis. Extensive clinico-demographic an...

journal_title：Alimentary pharmacology & therapeutics

authors： Stepanova M,Aquino R,Alsheddi A,Gupta R,Fang Y,Younossi Z

更新日期：2010-05-01 00:00:00

abstract：BACKGROUND:Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM:To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS:Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, ...

journal_title：Alimentary pharmacology & therapeutics

authors： Talley NJ,Riff DS,Schwartz H,Marcuard SP

更新日期：2001-10-01 00:00:00

abstract：BACKGROUND:The increasing incidence of Clostridium difficile (C. difficile) infection (CDI) among patients with inflammatory bowel disease is well recognised. However, most studies have focused on demonstrating that CDI is associated with adverse outcomes in IBD patients. Few have attempted to identify predictors of se...

journal_title：Alimentary pharmacology & therapeutics

authors： Ananthakrishnan AN,Guzman-Perez R,Gainer V,Cai T,Churchill S,Kohane I,Plenge RM,Murphy S

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND:Infliximab reduces mucosal inflammation in some, but not all, patients with Crohn's disease. AIM:To monitor clinical data and changes in mucosal cytokine levels after infliximab treatment to identify differences between responders and non-responders. METHODS:Twenty-six patients with fistulating Crohn's dis...

journal_title：Alimentary pharmacology & therapeutics

authors： Agnholt J,Dahlerup JF,Buntzen S,Tøttrup A,Nielsen SL,Lundorf E

更新日期：2003-03-01 00:00:00